Acute Repetitive Seizures Market Size

  • Report ID: 6448
  • Published Date: Sep 18, 2024
  • Report Format: PDF, PPT

Acute Repetitive Seizures Market Size

Acute Repetitive Seizures Market size is estimated at USD 3.84 billion in 2024 and is poised to reach USD 13.81 billion by the end of 2037, growing at around 15.2% CAGR during the forecast period i.e., between 2025-2037. In 2025, the industry size of acute repetitive seizures is evaluated at USD 4 billion.

The primary growth driver of the acute repetitive seizures (ARS) or cluster seizures is the increasing incidence of epilepsy and related neurological disorders, leading to a heightened demand for effective treatments and management strategies. This demand spurs advancements in drug development, medical devices, and diagnostic tools tailored to managing acute repetitive seizures, thereby expanding the acute repetitive seizures market. For instance, according to a 2021 study published by the National Library of Medicine (NLM), epilepsy affects 0.5-1% of the global population, corresponding approximately to 70 million people. It may be genetic in nature (idiopathic) or develop after brain damage, such as trauma, stroke, infection, tumor growth, or other structural or metabolic causes.

Additionally, the growing adoption of personalized medicine and improved access to healthcare services contribute to the acute repetitive seizures market expansion. Countries investing in healthcare infrastructure, such as the construction of new hospitals and clinics, increase the availability of specialized care for epilepsy and seizure disorders. Moreover, advances in telemedicine have made it easier for patients in remote or underserved areas to access specialist care.


Acute Repetitive Seizures Market Overview
Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:


Author Credits:  Radhika Pawar


  • Report ID: 6448
  • Published Date: Sep 18, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

The global acute repetitive seizures market is estimated at USD 4 billion in 2025.

Expanding at a CAGR of 15.2%, the global market is anticipated to increase from USD 3.84 billion in 2024 to USD 13.81 billion by 2037.

Some of the leading companies are UCB S.A., Belgium, Neurelis, Inc., Bausch Health Companies Inc., Alexza Pharmaceuticals, Inc., Veriton Pharma, Pfizer Inc. and Sanofi S.A.

USL-261 segment is estimated to dominate the market with a significant CAGR during the forecast period.

The market in North America is estimated to grow with the largest revenue share of 44.8% by the end of 2037.
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample